Determination of L-654,066, a new 5 alpha-reductase inhibitor in plasma by liquid chromatography/atmospheric pressure chemical ionization mass spectrometry.
L-654,066 is a new 5 alpha-reductase inhibitor. A sensitive and specific assay based on combined liquid chromatography/mass spectrometry has been developed for the determination of this drug candidate in plasma. The analyte was isolated from plasma by solid-phase extraction on a C-18 cartridge. A related substance, L-683,838, was used as the internal standard. Extracts were chromatographed on a 5 cm C18 reverse-phase high-performance liquid chromatography column interfaced via the heated nebulizer probe to a corona discharge chemical ionization source. The mass spectrometer was operated in the positive ion tandem mode. The method has sufficient sensitivity, precision, accuracy and selectivity for the analysis of clinical samples containing L-654,066 at concentrations in the range 0.5-20 ng ml-1. The chromatographic run time is less than 2 min.
Gilbert
J D
JD
Merck Sharp & Dohme Research Laboratories, West Point, Pennsylvania 19486.
Olah
T V
TV
Barrish
A
A
Greber
T F
TF
D001378:Azasteroids / Q000097:blood*; D002138:Calibration; D042944:Cholestenone 5 alpha-Reductase; D006801:Humans; D013058:Mass Spectrometry / Q000379:methods*; D010088:Oxidoreductases / Q000037:antagonists & inhibitors*; D011863:Radioimmunoassay
D001378:Azasteroids; C077586:(5alpha)-23-methyl-4-aza-21-norchol-1-ene-3,20-dione; D010088:Oxidoreductases; D042944:Cholestenone 5 alpha-Reductase